Novo Nordisk, Wegovy
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) label. This update in the European Union (EU) reflects new data indicating the product’s ability,
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Fake Ozempic: How batch numbers help criminal groups spread dangerous drugs
Fake Ozempic adds to a glut of counterfeit pharmaceuticals that kill around a million people each year, according to the WHO.
Criminal gangs are spreading dangerous fake weight-loss drugs across the world
Fake Ozempic adds to a glut of counterfeit pharmaceuticals that kill around a million people each year, according to the WHO.
Yahoo Finance16d
Ozempic shortages will hit some EU countries only - Novo Nordisk
STORY: The European Union faces intermittent shortages of Ozempic ... meet runaway demand for Ozempic and its related obesity drug Wegovy. Some analysts forecast the obesity drug market could ...
Millions in Department of Defense funds to be distributed
The Northeast Microelectronics Coalition Hub announced on Wednesday that it had been awarded $37.8 million in federal ...
Regulatory Oversight News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
AOL16d
Ozempic shortages in EU will not affect all member states - Novo Nordisk
LONDON (Reuters) - Intermittent shortages of diabetes drug Ozempic in the European Union that are expected ... to meet runaway demand for Ozempic and Wegovy, its obesity drug containing the ...